Fluorouracil

Dosage for Fluorouracil is highly individualized and must be calculated by an oncology specialist or dermatologist based on Body Surface Area (BSA), which uses height and weight.

Systemic Administration (IV):

• Colorectal Cancer: Standard bolus doses may range from 400 mg/m² to 500 mg/m² weekly or on specific days of a 28-day cycle. Continuous infusions (delivered via a pump over 24-46 hours) often use doses of 2400 mg/m² to 3000 mg/m² per cycle.
• Breast Cancer: Often administered as 500 mg/m² or 600 mg/m² on days 1 and 8 of a 21-day or 28-day cycle, frequently in combination with cyclophosphamide and methotrexate (CMF regimen).

Topical Administration (Cream/Solution):

• Actinic Keratosis: Typically applied once or twice daily for 2 to 4 weeks. The medication is applied thinly to the affected area using a non-metal applicator or gloved fingers.
• Superficial Basal Cell Carcinoma: A 5% cream is generally applied twice daily for at least 3 to 6 weeks, though treatment may continue for up to 12 weeks.

Fluorouracil is not commonly used in pediatric populations, and its safety and effectiveness in children have not been established by the FDA. If used off-label for rare pediatric malignancies, dosing is strictly determined by specialized pediatric oncologists and is based on pediatric-specific protocols.

Renal Impairment

While the kidneys are not the primary route of metabolism for the parent drug, renal impairment can lead to the accumulation of toxic metabolites. Healthcare providers may monitor kidney function (Creatinine Clearance) and may consider dose reductions in patients with severe renal failure.

Hepatic Impairment

Since the liver is the primary site of Fluorouracil metabolism (via the DPD enzyme), patients with significant liver dysfunction (elevated bilirubin or AST/ALT) are at a higher risk for toxicity. Dose adjustments or temporary suspension of therapy may be required for patients with jaundice or severe hepatic insufficiency.

Elderly Patients

Patients over the age of 65 may be more susceptible to the toxic effects of Fluorouracil, particularly gastrointestinal side effects (diarrhea, mucositis) and bone marrow suppression. Close monitoring and conservative starting doses are often employed in geriatric oncology.

Systemic (IV):

• This medication is administered in a clinical setting (hospital or infusion center) by trained healthcare professionals.
• If you are receiving a continuous infusion, you will be sent home with a portable 'CADD' pump. Ensure the tubing is not kinked and the pump is kept at the level recommended by your nurse.

Topical (Cream/Solution):

• Wash and Dry: Clean the area and wait 10-15 minutes for the skin to be completely dry before applying.
• Application: Use a thin layer. Avoid the eyes, nose, and mouth.
• Sun Protection: The treated skin will become very sensitive. Wear protective clothing and use sunblock on non-treated areas.
• Hand Hygiene: Wash hands thoroughly immediately after application, even if you used an applicator.
• Do Not Bandage: Unless specifically told by your doctor, do not cover the treated area with airtight dressings (occlusive dressings), as this increases absorption and toxicity risk.

• IV Therapy: If you miss an infusion appointment, contact your oncology clinic immediately to reschedule. Timing is critical for the effectiveness of chemotherapy cycles.
• Topical Therapy: If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not 'double up' to catch up.

Signs of systemic overdose include severe nausea, intractable vomiting, bloody diarrhea, extreme fatigue, and signs of infection (fever, chills) due to low white blood cell counts. For topical overdose (accidental ingestion or excessive application), symptoms may include stomach pain and severe skin irritation. In case of suspected overdose, contact the Poison Control Center or seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop treatment without medical guidance, as this can impact the success of your therapy.

Systemic Fluorouracil affects cells that divide rapidly, leading to several predictable side effects.

• Gastrointestinal Distress: Nausea and vomiting are common but usually manageable with modern antiemetic (anti-nausea) medications. Diarrhea can be more severe and may lead to dehydration.
• Mucositis and Stomatitis: This refers to painful sores or inflammation in the mouth and throat. It typically feels like a severe 'burning' sensation or multiple canker sores. Patients are often advised to suck on ice chips during the IV bolus to constrict blood vessels in the mouth and reduce drug delivery to these tissues.
• Myelosuppression: A decrease in bone marrow activity resulting in low white blood cells (leukopenia/neutropenia), which increases infection risk; low red blood cells (anemia), causing fatigue; and low platelets (thrombocytopenia), increasing bruising or bleeding risk.
• Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia): This is characterized by redness, swelling, pain, and sometimes peeling or blistering on the palms of the hands and soles of the feet. It can feel like a severe sunburn or a tingling 'pins and needles' sensation.
• Alopecia: Thinning of the hair or hair loss occurs in some patients, though it is usually less complete than with other chemotherapies like doxorubicin.

• Photosensitivity: Increased sensitivity to sunlight, leading to rapid burning.
• Hyperpigmentation: Darkening of the skin or along the veins where the drug was infused.
• Nail Changes: Nails may become brittle, develop ridges, or even detach from the nail bed (onycholysis).
• Lacrimation: Excessive tearing or irritation of the eyes (conjunctivitis).

• Cardiotoxicity: This can manifest as chest pain (angina), changes in heart rhythm (arrhythmias), or in rare cases, a heart attack. This is thought to be caused by coronary artery vasospasm (temporary tightening of the heart's arteries).
• Cerebellar Syndrome: A neurological condition causing lack of coordination, unsteady gait (ataxia), and slurred speech.
• Anaphylaxis: Severe, life-threatening allergic reactions.

> Warning: Stop using Fluorouracil (if topical) and call your doctor immediately or seek emergency care if you experience any of the following:

• Fever over 100.4°F (38°C): This could indicate 'febrile neutropenia,' a life-threatening lack of white blood cells during an infection.
• Severe Chest Pain: Especially if it radiates to the arm or jaw, or is accompanied by shortness of breath.
• Severe Diarrhea: More than 4-6 stools per day over your normal baseline, or any bloody stools.
• Confusion or Disorientation: Any sudden change in mental status or balance.
• Signs of DPD Deficiency: Rapid onset of severe mouth sores, uncontrollable diarrhea, and dangerously low blood counts shortly after the first dose.

Most side effects of Fluorouracil resolve after the medication is discontinued. However, some patients may experience 'chemo-brain' (lingering cognitive impairment or memory issues). Long-term skin changes, such as permanent hyperpigmentation or increased sun sensitivity, may occur following topical use. Unlike some other chemotherapies, Fluorouracil is not strongly associated with secondary cancers or permanent heart damage, though the acute cardiotoxic effects are a major concern during treatment.

While Fluorouracil does not always carry a traditional 'boxed warning' in the same format as newer drugs, the FDA-approved labeling contains 'Warnings' that are considered critical. The most significant is the warning regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency. Patients with this genetic trait cannot break down the drug, leading to extreme, potentially fatal toxicity involving the GI tract, bone marrow, and nervous system. Another critical warning involves Cardiotoxicity, requiring immediate cessation of the drug if cardiac symptoms occur.

Report any unusual symptoms to your healthcare provider immediately. Early intervention is key to managing chemotherapy side effects effectively.

Fluorouracil is a high-alert medication that requires careful supervision by an oncology or dermatology specialist. It is cytotoxic (cell-killing) and must be handled with extreme care. If you are using the topical cream, ensure that family members, children, and pets do not come into contact with the treated skin or the tube itself. Accidental ingestion by pets has been reported to be fatal.

While Fluorouracil does not have a formal 'Black Box' on all generic labels, the FDA-mandated 'Warnings' section highlights two life-threatening risks:

1. 1DPD Deficiency: Patients with a deficiency in the dihydropyrimidine dehydrogenase enzyme are at risk for severe, life-threatening toxicity from standard doses of Fluorouracil. Genetic testing is available and may be recommended by some clinicians before starting therapy.
2. 2Hospitalization: It is recommended that the initial 'loading' dose of systemic Fluorouracil be administered in a hospital setting where the patient can be closely monitored for acute reactions.

Allergic Reactions / Anaphylaxis Risk

Though rare, systemic Fluorouracil can cause severe allergic reactions. Patients should be monitored for hives, swelling of the face or throat, and difficulty breathing during and after infusion.

Cardiotoxicity

Fluorouracil can cause coronary vasospasm. Patients with a history of heart disease or coronary artery disease are at higher risk. If you experience chest pain, pressure, or a racing heart, the drug must be stopped immediately and usually should not be restarted.

Hematologic Toxicity (Bone Marrow Suppression)

Fluorouracil significantly lowers the body's ability to produce white blood cells, red blood cells, and platelets. This 'nadir' (the lowest point of blood counts) typically occurs between 9 and 14 days after the start of a treatment cycle.

Gastrointestinal Toxicity

Severe inflammation of the digestive tract can lead to dehydration and sepsis (blood infection). Treatment must be paused if severe diarrhea or mouth sores occur.

Patients undergoing systemic Fluorouracil therapy require frequent laboratory monitoring:

• Complete Blood Count (CBC): To monitor for neutropenia and anemia, usually performed before every dose.
• Liver Function Tests (LFTs): To ensure the liver can process the medication (bilirubin, ALT, AST).
• Kidney Function: Monitoring serum creatinine and GFR.
• Cardiac Monitoring: For patients with pre-existing heart conditions, an EKG or stress test may be required before starting.

Fluorouracil may cause dizziness, confusion, or visual changes in some patients. Do not drive or operate heavy machinery until you know how the medication affects you. If you experience 'ataxia' (unsteadiness on your feet), avoid these activities and contact your doctor.

Alcohol should be avoided or strictly limited during Fluorouracil therapy. Alcohol can worsen gastrointestinal irritation and may increase the risk of liver toxicity. Furthermore, alcohol can contribute to dehydration, which is a significant risk for patients experiencing Fluorouracil-induced diarrhea.

Systemic Fluorouracil does not require a tapering period, but the decision to stop therapy is complex and must be made by an oncologist. If the drug is stopped due to toxicity (like cardiotoxicity), it is often discontinued permanently. For topical use, stopping too early may result in the recurrence of the skin lesions.

> Important: Discuss all your medical conditions, especially any history of heart disease or genetic enzyme deficiencies, with your healthcare provider before starting Fluorouracil.

• Brivudine/Sorivudine: These antiviral medications (used for shingles) are strictly contraindicated with Fluorouracil. They irreversibly inhibit the DPD enzyme, which prevents the breakdown of Fluorouracil. Using these together can lead to fatal toxicity. A waiting period of at least 4 weeks is required between stopping Brivudine and starting Fluorouracil.

• Warfarin (Coumadin): Fluorouracil can significantly increase the blood-thinning effects of warfarin, leading to a high risk of life-threatening bleeding. Patients on warfarin will need very frequent INR (blood clotting) monitoring and likely a dose reduction of their blood thinner.
• Leucovorin (Folinic Acid): While often given intentionally with Fluorouracil to increase its efficacy (especially in colorectal cancer), Leucovorin also increases the toxicity of Fluorouracil. This combination requires expert management to balance the 'kill rate' of the cancer with the safety of the patient.
• Phenytoin (Dilantin): Fluorouracil may increase the levels of phenytoin in the blood, potentially leading to phenytoin toxicity (symptoms include ataxia, confusion, and slurred speech).
• Live Vaccines: Because Fluorouracil suppresses the immune system, receiving live vaccines (like the MMR or yellow fever vaccine) can lead to a severe infection from the vaccine itself. Live vaccines should be avoided during and for several months after chemotherapy.

• Metronidazole: This antibiotic may decrease the clearance of Fluorouracil, slightly increasing the risk of side effects.
• Cimetidine: Used for heartburn, cimetidine may increase the plasma concentration of Fluorouracil by interfering with its metabolism.

• General Nutrition: There are no specific 'forbidden' foods like grapefruit, but patients are encouraged to follow a 'bland' diet (BRAT diet: Bananas, Rice, Applesauce, Toast) if they develop GI side effects.
• Hydration: It is vital to increase fluid intake to help the kidneys process the metabolites of the drug.

• St. John's Wort: May affect the metabolism of various drugs, though its specific impact on 5-FU is less clear than with other chemotherapies. It is generally avoided.
• Antioxidants (High-dose Vitamin C, E): Some oncologists advise against high-dose antioxidant supplements during chemotherapy, as they might theoretically protect cancer cells from the oxidative damage intended by the treatment.

• Thyroid Function Tests: Fluorouracil may cause a false increase in T4 and T3 levels due to changes in protein binding, though the patient remains 'euthyroid' (normal thyroid function).
• Bilirubin and 5-HIAA: Fluorouracil may interfere with the accuracy of tests measuring these substances in the urine or blood.

For each major interaction, the primary concern is either the inhibition of the DPD enzyme (leading to toxicity) or the suppression of the immune system (leading to vaccine-related illness). Management strategies always involve frequent blood work and dose adjustments.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter creams if you are using topical Fluorouracil.

There are several scenarios where Fluorouracil must NEVER be used because the risks outweigh any possible benefit:

• Known DPD Deficiency: Patients confirmed to have a complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme must not receive Fluorouracil. Without this enzyme, the drug reaches lethal levels in the body almost immediately.
• Severe Bone Marrow Suppression: Patients with baseline white blood cell counts that are dangerously low (neutropenia) or very low platelet counts should not start treatment until their marrow recovers.
• Pregnancy (Topical Use): Topical Fluorouracil is strictly contraindicated in pregnancy (Category X) because it can cause fetal harm even with low systemic absorption.
• Previous Severe Reaction: If a patient has previously experienced a life-threatening reaction to Fluorouracil or its prodrug, Capecitabine, they should not be re-exposed.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Poor Nutritional Status: Patients who are severely malnourished or emaciated are at a much higher risk for severe GI toxicity and may not tolerate the drug.
• Active Infection: Chemotherapy should generally be delayed until an active, serious infection is resolved, as Fluorouracil will further weaken the immune response.
• History of Heart Disease: Due to the risk of coronary vasospasm, patients with unstable angina or recent heart attack require extreme caution and continuous monitoring.
• Elderly/Frailty: The 'biological age' and overall frailty of the patient may make the standard dose of Fluorouracil too toxic.

• Capecitabine (Xeloda): This is an oral drug that the body converts into Fluorouracil. If you are allergic to or cannot tolerate Capecitabine, you will likely have the same reaction to Fluorouracil.
• Teysuno (S-1): Another fluoropyrimidine-based drug used in some regions; it shares the same metabolic pathway and risks.

> Important: Your healthcare provider will evaluate your complete medical history, including any genetic testing and your current physical strength, before prescribing Fluorouracil.

Fluorouracil is considered highly hazardous during pregnancy.

• Systemic Use: Classified as FDA Category D. There is clear evidence of human fetal risk based on its mechanism of action (interfering with DNA synthesis). It should only be used in pregnant women if the life of the mother is at stake and no other treatment is available.
• Topical Use: Classified as FDA Category X. Because topical treatment for skin conditions is generally elective or can be delayed, it must never be used during pregnancy.
• Contraception: Both men and women of childbearing potential should use highly effective contraception during treatment and for at least 3 to 6 months after the final dose.

It is not known if Fluorouracil passes into human breast milk. However, because of the potential for serious adverse reactions and the drug's known toxicity to rapidly dividing cells, breastfeeding is strictly discouraged while taking this medication. Most clinicians recommend waiting at least several weeks after the final dose before resuming breastfeeding.

Fluorouracil is not FDA-approved for use in children. Its safety profile in pediatric patients has not been established. In rare cases where it is used for pediatric cancers, it is done under strict clinical trial protocols. Children may be more sensitive to the bone marrow-suppressive effects of the drug.

Patients over age 65 are at a significantly increased risk for severe toxicity, particularly GI effects (diarrhea, mouth sores) and infectious complications from low white blood cell counts. Geriatric patients often have a lower 'functional reserve' in their kidneys and liver, and they are more likely to be taking interacting medications like warfarin. Oncologists often use 'geriatric assessment tools' to determine if a dose reduction is necessary for older adults.

While Fluorouracil is primarily metabolized by the liver, its metabolites are cleared by the kidneys. In patients with a GFR below 30 mL/min, the risk of side effects increases. No specific formula-based dose adjustment is mandated by the FDA, but clinical judgment and close monitoring of blood counts are required.

Since the DPD enzyme is primarily located in the liver, significant hepatic dysfunction can impair the body's ability to clear Fluorouracil. Patients with a bilirubin level > 5 mg/dL are generally not candidates for systemic Fluorouracil. Those with moderate impairment (bilirubin 2-5 mg/dL) usually require a 25% to 50% dose reduction.

> Important: Special populations require individualized medical assessment. Always inform your specialist about your age, pregnancy status, or any history of organ failure.

Fluorouracil (5-FU) is a pyrimidine analogue that functions as an antimetabolite. Its primary molecular target is the enzyme thymidylate synthase (TS).

1. 1TS Inhibition: 5-FU is converted to FdUMP, which forms a stable covalent complex with thymidylate synthase and a reduced folate cofactor. This 'locks' the enzyme, preventing the conversion of deoxyuridylate (dUMP) to thymidylate (dTMP). Without dTMP, the cell cannot produce thymidine triphosphate (dTTP), leading to the cessation of DNA synthesis.
2. 2RNA Incorporation: 5-FU is also converted to FUTP, which is incorporated into RNA. This disrupts the processing of ribosomal RNA and the splicing of messenger RNA, leading to 'RNA stress' and cell death.
3. 3DNA Incorporation: FdUTP can be incorporated into DNA, causing strand breaks and triggering the DNA repair machinery, which often fails and leads to apoptosis.

Fluorouracil is 'cell-cycle specific,' meaning it primarily kills cells during the S-phase (the DNA synthesis phase) of the cell cycle. Because of its short half-life, the duration of exposure is critical. This is why continuous infusions (over 24-96 hours) are often more effective and less toxic than large 'bolus' injections for certain types of cancer.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); 2-6% (Topical) |

| Protein Binding | 8% to 12% (Low) |

| Half-life | 10 to 20 minutes (Parent drug) |

| Tmax | End of infusion (IV); 1-3 hours (Topical) |

| Metabolism | 80% hepatic via DPD enzyme |

| Excretion | Renal (7% to 20% as parent/metabolites); Lungs (60-80% as CO2) |

• Molecular Formula: C4H3FN2O2
• Molecular Weight: 130.08 g/mol
• Solubility: Sparingly soluble in water; soluble in alcohol.
• Structure: A pyrimidine base (uracil) with a fluorine atom at the 5-carbon position.

Fluorouracil is classified as a Nucleoside Metabolic Inhibitor [EPC] and a Fluoropyrimidine Antimetabolite. It is chemically related to Capecitabine (an oral prodrug) and Floxuridine.